louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05729438: Nutritional Assesment in Patients With Cirrhosis
Official title: Nutritional Assesment in Patients With Cirrhosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cirrhosis, Liver
Lead sponsor: SUUMC Central Military Hospital Dr Carol Davila
Sponsor class: OTHER
First posted: 2023-02-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients males and females with hepatic cirrhosis

Brief summary: This study aims to evaluated nutritional status in patiets with cirrhosis


Eligibility criteria: Inclusion Criteria:

* signed informed consent
* age \>18, \<75 years old
* hepatic cirrhosis diagnosis

Exclusion Criteria:

* refuse to participate/to give consent
* presence of musculo-skeletal disease previous diagnosed, neuropathic diseases, malignancy

Primary outcomes:
measure: muscle mass change
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: București
country: Romania
facility: Suumc
state: București - Sector1
Study officials:
References:
Clinical trial NCT02115438: A Cohort Study for Occupational Stress Induced Early Embryonic Death
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Etiology
Cohort Study
Early Embryonic Death
Occupational Stress
Occupational Epidemiology
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2014-04-16
Enrollment: 3405
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnant women with job

Brief summary: Occupation stress can be the risk factors of early embryonic death


Eligibility criteria: Inclusion Criteria:

1. Pregnant women and their spouses in the gynecology clinic patients and wish to create the cards in the hospital;
2. the gestational age is less than 14 weeks;
3. pregnant women and their spouses have jobs before treatment.

Exclusion Criteria:

Do not sign the informed consent.

Primary outcomes:
measure: early embryonic death
timeFrame: 20 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02519738: Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion
Official title: Granulation Tissue at G Tube Site: Treatment With Kenalog vs Chemical Cauterization With Silver Nitrate vs Soap Washcloth Abrasion
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Other Abnormal Granulation Tissue Nos
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2015-08-11
Enrollment: 52
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Granulation tissue, or excess tissue, forms around gastrostomy tube sites and is a common problem seen in the pediatric surgery population. There is no standard treatment that has been identified in clinical practice to treat granulation tissue effectively. Clinicians prescribe treatments of varying nature to help treat this condition. By conducting this study, the investigators hope to identify if there is any difference in the treatment groups and if there is any superiority for one treatment over the other. The three arms in the study are Silver Nitrate treatment, treatment with Kenalog, and Washcloth abrasion. Treatments will continue over a period of three weeks, and the progress will be followed using surveys and photographs.

Detailed description: Hypergranulation tissue surrounding gastrostomy tube sites in pediatric patients is a significant problem. This tissue may cause drainage or bleeding that bothers patients and parents. Numerous methods of treatment are used for treatment of hypergranulation tissue, but no data exists to support one method of treatment over another. The investigators plan to perform a prospective randomized trial of three different therapies (silver nitrate cauterization, topical kenalog, and soap cloth abrasion) to identify the best treatment modality. Participants will be followed via office visit at four and eight weeks after initiation of therapy. Measurements of the granulation tissue and photographs will be obtained pre treatment and at each post treatment visit. In addition parents will be asked to fill out a pre and post treatment survey regarding improvement in symptoms. Investigators plan to enroll 120 patients total with the intention of having 40 participants in each group.

Eligibility criteria: Inclusion Criteria:

* Any patient falling within age group with granulation tissue around G tube site

Exclusion Criteria:

* Patients falling outside of age group range

Primary outcomes:
measure: Decrease in Size (mm) of Granulation Tissue
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: C.S. Mott Children's Hospital, University of Michigan
state: Michigan
Study officials:
affiliation: Univeristy of Michigan
name: Ronald B Hirschl, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06684938: US Guided Sacroiliac Joint Injection
Official title: Predictors of Outcome for Sacroiliac Joint Injection with Local Anaesthetic and Corticosteroids in Sacroiliac Joint Pain Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pain
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-11-12
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Sacroiliac joint (SIJ) pain is one of the underappreciated causes of low back pain. Recent studies have reported excellent outcomes after Ultrasound (US) guided SIJ injection with local anesthetics and corticosteroids, but these studies are characterized by wide variability in selection criteria and patient characteristics; therefore, there is a need to determine whether any demographic or clinical variables can be used to predict US-guided SIJ injection outcomes.

Detailed description: this study is testing the different predictors related to the patient that could affect his improvement by \>50% after US guided SIJ injection with anaesthetic and steroids

Eligibility criteria: Inclusion Criteria:

* sacroiliac pain

Exclusion Criteria:

-

Primary outcomes:
measure: postinjection sacroiliac pain intensity
timeFrame: 3 months
measure: postinjection disability questionnairre
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Sherine El-Sherif
city: Alexandria
country: Egypt
facility: Alexandria University
Study officials:
affiliation: Alexandria University
name: SHERINE EL-SHERIF
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06565338: Comparison Between Effect of Vitamin D Versus Dexmedetomidine in Patients with Head Trauma Using Interleukin 6
Official title: Comparison Between the Neuroprotective Effect of Vitamin D Versus Dexmedetomidine in Patients with Traumatic Brain Injury Using Interleukin 6 As Inflammatory Marker
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Traumatic Brain Injury
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with traumatic brain injury with GCS 8-12

Brief summary: in this study the investigators compare between the neuroprotective effect of vitamin d versus dexmedetomidine in patients with traumatic brain injury using interleukin 6 as inflammatory biomarker

Detailed description: patients with moderate head trauma (GCS 8-12) within first 24 hours were randomly divided into 2 groups, first group received 100,000 IU of vitamin D was given IM \& the other group received dexmedetomidine 0.4 mic/kg as loading dose then 0.25 mic/kg/hr as maintainence dose for 5 days detecting APATCHE at admission and following up of vital signs (HR \& NIBP) \& investigations (CBC \& RFT\& ABG \& ESR\& CRP \& IL-6) \& GCS and GOS for 5 days.

Eligibility criteria: Inclusion Criteria:

* Both Gender.
* Age (18-50)
* GCS (8-12)
* Pt with traumatic brain insult who not indicated surgical intervention

Exclusion Criteria:

* Prior severe disability.
* Isolated brain system lesions.
* History of underlying neurologic, metabolic or psychiatric disorders.
* Alcohol or drug abuse.
* Pregnancy.
* Patients with intracranial hemorrhage who indicated surgical evacuation.
* Multisystem life-threatening trauma.
* GCS \> 12 \& \<8.
* Vitamin d deficiency.

Primary outcomes:
measure: The primary endpoint aims to measure the inflammatory markers level:
timeFrame: 5 days
measure: Primary outcome measure
timeFrame: 5 days
measure: Primary outcome measure
timeFrame: 5 days
Secondary outcomes:
measure: The secondary endpoints aim to compare ICU stay, morbidity and mortality in both groups:
timeFrame: 3 months
measure: Secondary outcome measure
timeFrame: 3 month
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Asmaa
Study officials:
affiliation: Minia University
name: ahmed ezz
role: STUDY_CHAIR
References:
Clinical trial NCT04867538: The Cholelithiasis in Adults With Short Bowel Syndrome
Official title: Prevalence, Risk Factors, and Complications of Cholelithiasis in Adults With Short Bowel Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Short Bowel Syndrome
Keywords: Short bowel syndrome
Cholelithiasis
Prevalence
Risk factors
Lead sponsor: Jinling Hospital, China
Sponsor class: OTHER
First posted: 2021-04-30
Enrollment: 345
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: SBS was defined as intestinal malabsorption disorder caused by extensive bowel resection with a remnant small intestine length of \<200cm

Brief summary: Short-term studies have shown that patients with short bowel syndrome (SBS) often develop cholestasis or cholelithiasis. In this retrospective cohort study, we aimed to define the incidence, risk factors, and clinical consequences of cholelithiasis in adults with SBS over an extended time period.

Detailed description: However, only limited data are available regarding cholelithiasis in patients with SBS. The prevalence of cholelithiasis in patients with SBS has been reported only in two studies. Furthermore, few studies have focused on identifying the risk factors for cholelithiasis in patients with SBS. Considering the marked improvements in medical care and nutrition support during the last 2 decades, the current incidence and risk factors for cholelithiasis in patients with SBS are unknown.

The aim of the current study was to provide comprehensive, longitudinal, and long-term data on the incidence of symptomatic and asymptomatic cholelithiasis in a cohort of patients with SBS, in order to identify the prevalence, risk factors, and clinical consequences of cholelithiasis in patients with SBS to aid in the development of protective interventions.

Eligibility criteria: Inclusion Criteria:

All eligible adults diagnosed with SBS

Exclusion Criteria:

age \<18 years; history of cholelithiasis before SBS diagnosis; cholecystectomy; biliary tract obstruction or no abdominal imaging (CT, MRI, or ultrasound) after SBS diagnosis.

Primary outcomes:
measure: the incidence of cholelithiasis in patients with SBS
timeFrame: 2010/1/1-2019/12/31
measure: risk factors
timeFrame: 2010/1/1-2019/12/31
measure: complications
timeFrame: 2010/1/1-2019/12/31
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Gao X, Zhang L, Wang S, Xiao Y, Song D, Zhou D, Wang X. Prevalence, Risk Factors, and Complications of Cholelithiasis in Adults With Short Bowel Syndrome: A Longitudinal Cohort Study. Front Nutr. 2021 Nov 29;8:762240. doi: 10.3389/fnut.2021.762240. eCollection 2021.
Clinical trial NCT03525938: Transversus Abdominis Plane Block for Chronic Postsurgical Orchalgia
Official title: Transversus Abdominis Plane Block for Chronic Postsurgical Orchalgia: SHAM Controlled, Randomized Trial, Three Months Results
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Post-surgical Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-05-16
Enrollment: 70
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the study will evaluate the effect of transversus abdominis plane block (TAP) on chronic post-groin surgeries orchalgia (chronic testicular pain)


Eligibility criteria: Inclusion Criteria:

* The inclusion criteria were patients with chronic scrotal pain (orchialgia) that fulfilled the following criteria:

  1. pain intensity ≥ 5 on the visual analog scale (VAS),
  2. pain that lasted for more than 3 months after groin surgeries,
  3. failed conservative treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

* The exclusion criteria were:

  1. patients with other causes of scrotal pain, e.g., epididymitis, orchitis, and hydrocele,
  2. patients complaining of groin infection and coagulopathy,
  3. patients suffering from hypertension, ischemic heart disease, or psychiatric disorders

Primary outcomes:
measure: The change of intensity of pain measured by Visual Analogue Pain (VAS ) score
timeFrame: The pain assessment will be done one month, 2 month and 3 month postprocedure.
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Diab
state: Assuit
Study officials:
References:
Clinical trial NCT03022838: The Effects of Caffeine Withdrawal on Migraine
Official title: The Effects of Caffeine Withdrawal on Migraine - a Randomized, Double-blind, Crossover Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Migraine
Caffeine Withdrawal
Lead sponsor: Nordlandssykehuset HF
Sponsor class: OTHER
Collaborators: name: King's College London
name: University Hospital of North Norway
First posted: 2017-01-18
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Sporadic and chronic dietary consumption of caffeine has substantial biological effects on the nervous system. The effects on migraine are at large not known. In this study we want to assess the effects of caffeine withdrawal on migraine.

Detailed description: The actions of caffeine as an antagonist of adenosine receptors have been extensively studied, and there is no doubt that both daily and sporadic dietary consumption of caffeine has substantial biological effects on the nervous system. The current opinion is that caffeine both can cure and trigger headaches. Caffeine is a component of many combination drugs marketed for the relief of headaches, but on the other hand it is strongly incriminated as a risk factor for developing chronic headache. Withdrawal may cause symptom constellations similar to the migraine syndrome. Further, caffeine consumption may affect sleep and alertness, possibly influencing the risk of migraine attacks. .

Eligibility criteria: Inclusion Criteria:

* migraine present for at least 1 year and fulfilling diagnostic criteria (ICHD-3 beta)
* =/\> 3 migraine attacks per month
* no migraine prophylaxis the last month
* consumption =/\> 300 mg and \</= 800 mg caffeine per day the last month
* signed consent

Exclusion Criteria:

* suspicion of medication-overuse headache
* pregnancy and breast feeding
* serious co-morbidity or conditions requiring Medical treatment or caution
* working night shift
* use of drugs with moderate or major interactions with caffeine

Primary outcomes:
measure: Migraine days
timeFrame: 10 weeks
Secondary outcomes:
measure: Withdrawal symptoms and/or syndrome (according to criteria)
timeFrame: 2 first days after caffeine withdrawal(withdrawal vs. caffeine)
measure: Migraine attacks
timeFrame: 10 weeks
measure: Sleep improvement
timeFrame: 10 weeks
measure: Quality of life
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Bodø
country: Norway
facility: Nordland Hospital
city: Bodø
country: Norway
facility: Departement of Neurology, NLSH HF
city: Tromsø
country: Norway
facility: Departement of Neurology
Study officials:
affiliation: Department for research and patient safety, Nordland Hospital trust
name: Jan T Henriksen
role: STUDY_DIRECTOR
References:
Clinical trial NCT04586738: Efficacy and Safety of Non-resorbable Uveoscleral Implant Versus Absorbable Collagen Matrix in Non-perforating Deep Sclerectomy
Official title: Comparative Clinical Trial on the Efficacy and Safety of Non-resorbable Uveoscleral Implant Associated With Absorbable Collagen Matrix vs Isolated Absorbable Collagen Matrix in Non-perforating Deep Sclerectomy in Glaucoma Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Glaucoma
Lead sponsor: Germans Trias i Pujol Hospital
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of the study is to evaluate and compare the hypotensive efficacy at 24 months between non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix versus non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant.

Detailed description: The aim of this study is to evaluate and compare the hypotensive efficacy at 24 months between two implants in glaucoma surgery. Non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix versus non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant.

Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years of age
* Primary or secondary open-angle glaucoma
* High intraocular pressure (greater than or equal to 18mmHg) despite using maximum medical treatment
* Intolerance to medication.

Exclusion Criteria:

* Patients with previous glaucoma surgery
* Previous ocular surgery in the last 6 months
* Previous history of Laser trabeculoplasty in the last 12 months
* Moderate or severe diabetic retinopathy
* Active or recurrent eye disease (uveitis)
* Plateau iris
* Ocular neovascularization
* Aphakia
* Neovascular angle-closure glaucoma
* Previous history of intraocular or extraocular malignant neoplasm
* Pregnancy or lactation period, axial length\> 26mm and \<20mm
* Unwillingness for participating

Primary outcomes:
measure: Number of Intraocular pressure
timeFrame: 24 hours after surgery, 3 months, 12 months, 24 months
Secondary outcomes:
measure: Number of adverse events
timeFrame: 24 hours after surgery, 3 months, 12 months, 24 months
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Jéssica Botella García
city: Barcelona
country: Spain
facility: Hospital Universitario Germans Trias i Pujol
Study officials:
affiliation: Germans Trias i Pujol Hospital
name: Jéssica Botella García, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05217238: Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium
Official title: Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rocuronium
Injection Pain
Lead sponsor: Yangzhou University
Sponsor class: OTHER
First posted: 2022-02-01
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of quick effect, no histamine release and accumulation and no obvious cardiovascular adverse reactions, so it has been widely used in clinical anesthesia induction. However, when given intravenously, rocuronium can cause adverse reactions such as injection pain and limb retraction, which can lead to needle prolapse, extravasation of injection drugs, swelling of injection site, serious induction delay, and cardiovascular adverse events in severe cases. Remifentanil is a synthetic opioid drug hydrolyzed by esterase. Compared with other opioid drugs, remifentanil has the advantages of quick effect, short half-life and short time of hemodynamic changes, so it is an ideal analgesic in clinical anesthesia. In this study, in order to provide clinical references, sequential method was used to find the median effective dose (ED50) by means of pre-intravenous injection of Remifentanil to suppress pain in rocuronium injection.


Eligibility criteria: Inclusion Criteria:

1. Ages ranged from 18 to 80.
2. ASA # or # level.

Exclusion Criteria:

* Allergy or contraindication to remifentanil or rocuronium; required for Central venipuncture catheterization;
* Abnormal liver or kidney function;
* Heavy drinking and long-term use of sedatives, analgesics or anti-anxiety drugs;
* Hearing and language impairment;
* Peripheral vascular disease;
* Severe cardiovascular disease or neurological disorders;
* Failure of one-time peripheral venipuncture;
* Infection of hand or wrist skin.

Primary outcomes:
measure: The appearance of intravenous injection pain Yes or No
timeFrame: an average of 2 minutes
Secondary outcomes:
measure: The levels of intravenous injection pain
timeFrame: an average of 2 minutes
Other outcomes:
measure: If any adverse memory or pain during the induction of general anesthesia
timeFrame: the time one hour after turn into Postanesthesia care unit
Locations:
city: Yangzhou
country: China
facility: the Affiliated Hospital of Yangzhou University
state: Jiangsu
Study officials:
References: